Clinical Trial Update: Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating niraparib for metastatic melanoma with homologous recombination mutations; efficacy and safety data not specified in snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: California Pacific Medical Center Research Institute | Conditions: Metastatic Melanoma | Phase 2 | Status: UNKNOWN